New Launch23 Jul 2025, 09:43 am
Sigachi Industries to Commence R&D Operations for API Development
AI Summary
Sigachi Industries, a leading player in pharmaceutical excipients, APIs, and specialty ingredients, is set to strengthen its scientific and technical capabilities with the commencement of operations at its newly established R&D Center in Hyderabad. The R&D Center will drive end-to-end API development, from lab-scale innovation to commercialization and global regulatory filings. The strategic API pipeline includes Sitagliptin phosphate monohydrate, Rivaroxaban, Bempedoic acid, Imeglimin HCI, Fimasartan potassium trihydrate, and Bilastine for various therapeutic segments. The R&D team will consist of 32-35 skilled scientists with a focus on quality-by-design and regulatory preparedness.
Key Highlights
- Sigachi Industries to commence R&D operations for API development
- Newly established R&D Center in Hyderabad
- End-to-end API development from lab-scale innovation to commercialization and global regulatory filings
- Strategic API pipeline targeting both commercialization and CEP filings across priority therapeutic segments
- Dedicated team of 32-35 skilled R&D scientists focused on accelerating product development for regulated markets